Fed Circ to rehear $235m ‘skinny label’ case

The US Court of Appeals for the Federal Circuit has agreed to reconsider its precedential ruling against Teva Pharmaceuticals for producing a generic hypertension and heart failure treatment, according to a Bloomberg Law report.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fed Circuit split over $235m skinny label verdict

10 August 2021 The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.

Generics

Amgen, Teva to face Sensipar monopoly claims

3 December 2020 Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.

Americas

Actavis and Teva sued over narcotic addiction generic

1 March 2017 Speciality pharmaceutical company Orexo has filed a complaint against Actavis and its parent company Teva for infringing patents protecting Orexo’s Suboxone and Subutex.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Fed Circ to rehear $235m ‘skinny label’ case

More on this story

Editor's picks

Editor's picks

More features